Compare · CI vs VRDN
CI vs VRDN
Side-by-side comparison of The Cigna Group (CI) and Viridian Therapeutics Inc. (VRDN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and VRDN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $78.25B, about 48.1x VRDN ($1.63B).
- Over the past year, CI is down 4.6% and VRDN is down 2.1% - VRDN leads by 2.5 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Viridian Therapeutics Inc.
- Price
- $295.88+0.30%
- $15.76-3.37%
- Market cap
- $78.25B
- $1.63B
- 1M return
- +2.39%
- -8.43%
- 1Y return
- -4.59%
- -2.08%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Viridian Therapeutics Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group
Latest VRDN
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- Viridian Therapeutics to Participate in Upcoming June Investor Conferences
- SEC Form 8-K filed by Viridian Therapeutics Inc.
- Director Fairmount Funds Management Llc bought $19,999,990 worth of shares (1,176,470 units at $17.00) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Viridian Therapeutics Inc.
- Viridian Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form 424B5 filed by Viridian Therapeutics Inc.
- SEC Form FWP filed by Viridian Therapeutics Inc.